New PI3K-Delta Inhibitor Umbralisib: Greater Then 50% Res...

New PI3K-Delta Inhibitor Umbralisib: Greater Then 50% Response Rate, Remissions Lasting For Over A Year
3 years 42 Views
Category:
Description:
Josh Brody MD @joshuabrodyMD Of Icahn School of Medicine at Mount Sinai Discusses New PI3K-Delta Inhibitor Umbralisib: Greater Then 50% Response Rate, Remissions Lasting For Over A Year.